---
id: regenerative-medicine
name: Regenerative Medicine
family: technological
tier: active
url: https://futuremap.talin.digital/e/regenerative-medicine/
license: CC-BY-NC-4.0
---

# Regenerative Medicine

> Repairing or replacing damaged tissue and organs rather than managing their decline.

## Maturity
2/5 — Approved products exist and are deployed for narrow indications; commercial viability, not science, is the binding constraint, and complex organ regeneration remains preclinical.

Capability 4 · deployment 2 · absorption 3 · bound by capital · improving

Source: EMA CAT quarterly highlights (EMA/147429/2026): 31 ATMPs authorised Dec 2008–Dec 2025, 7 withdrawn and 2 expired. Peer-reviewed: Int. J. Technology Assessment in Health Care (2024) — 22% of EMA-authorised ATMPs withdrawn, six of seven for COMMERCIAL reasons, not safety or efficacy. FDA lists 40+ approved cell and gene therapy products. ⚠ No bioprinted or lab-grown SOLID organ has been implanted in a human with an established outcome (2008–2026)

## What it is
Repairing or replacing damaged tissue and organs — stem cell therapies, tissue engineering and organ regeneration.

## What it does
It would shift medicine from managing degeneration to reversing it, which is what separates lifespan extension from healthspan extension.

## Common misconception
That the field is close to organ replacement. Approved therapies exist in narrow indications; complex organ regeneration remains early, and the gap between those two facts is where most overclaiming happens.

## Steepens
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap) — large
- The Silver Economy (the-silver-economy) — moderate
- The Care Economy (the-care-economy) — moderate

## What would change its gradient
- Manufacturing at cost — cell therapies are made per patient, which is a scale problem
- Vascularisation, the central technical barrier to complex tissue
- Reimbursement pathways for one-time high-cost interventions
